GPP
ADMS

Great Point Partners’s Adamas Pharmaceuticals ADMS Stock Holding History

Great Point Partners’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-256,340
Closed -$5.43M – 49
2017
Q3 		$5.43M Sell
256,340
-1,960,011
-88% -$35.9M 1.06% 27
2017
Q2 		$38.8M Sell
2,216,351
-385,000
-15% -$6.37M 6.94% 2
2017
Q1 		$45.5M Hold
2,601,351
– – 9.04% 1
2016
Q4 		$44M Hold
2,601,351
– – 9.03% 1
2016
Q3 		$42.7M Buy
2,601,351
+492,252
+23% +$7.48M 10.89% 2
2016
Q2 		$31.9M Hold
2,109,099
– – 9.14% 1
2016
Q1 		$30.5M Buy
2,109,099
+671,764
+47% +$11.3M 10.94% 1
2015
Q4 		$40.7M Buy
1,437,335
+327,335
+29% +$5.51M 17.08% 1
2015
Q3 		$18.6M Buy
1,110,000
+337,400
+44% +$7.68M 7.35% 4
2015
Q2 		$20.3M Buy
772,600
+163,950
+27% +$3.19M 7.9% 2
2015
Q1 		$10.6M Buy
608,650
+437,834
+256% +$7.5M 4.68% 5
2014
Q4 		$2.97M Buy
+170,816
New +$2.59M 1.43% 19

Other funds holding ADMS

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BWCA
Brenner West Capital Advisors New York $804M AUM 16.19% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Great Point Partners's ADMS Position: Q4 2017 in Review

Great Point Partners sold out of Adamas Pharmaceuticals (ADMS) in Q4 2017, closing a stake of 256,340 shares — an estimated $5.43M sold.

Great Point Partners first reported a position in ADMS in Q4 2014 and held it in 12 quarters. The position peaked at $45.5M in Q1 2017. 117 funds tracked by Wall St. Rank hold ADMS as of Q4 2017.

  • Great Point Partners reported no remaining Adamas Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Great Point Partners sold 256,340 Adamas Pharmaceuticals shares in Q4 2017, an estimated $5.43M.
  • Great Point Partners first reported a position in Adamas Pharmaceuticals in Q4 2014 and held it in 12 quarters.
  • Great Point Partners's Adamas Pharmaceuticals position peaked at $45.5M in Q1 2017.
  • 117 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2017.

Based on Great Point Partners's 13F filing for Q4 2017, filed 14 Feb 2018.